Highlights Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
42.12 ^USD	-0.40%		-1.98%	+18.38%

Apr. 17	Crinetics Pharmaceuticals Insider Sold Shares Worth $639,256, According to a Recent SEC Filing	MT
Mar. 26	Crinetics Pharmaceuticals Insider Sold Shares Worth $1,433,675, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Crinetics Pharma's hormonal disorder drug meets main goal in late-stage study	Mar. 19	RE
Crinetics Pharmaceuticals, Inc. Announces Positive Topline Results from PATHFNDR-2, Second of Two Phase 3 Studies Evaluating Efficacy and Safety of Oral, Once-Daily Investigational Paltusotine for Treatment of Acromegaly	Mar. 19	CI
Crinetics Pharmaceuticals Up in Extended Hours After Positive Top-Line Results for Drug Candidate	Mar. 12	MT
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome	Mar. 12	CI
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Crinetics' Once-Daily Oral Paltusotine Achieves the Primary and All Secondary Endpoints in the Phase 3 Pathfr-1 Study Evaluating Treatment of Patients with Acromegaly	23-09-10	CI
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Crinetics Pharmaceuticals, Inc. Presents Efficacy, Safety and Patient-Reported Outcome Data At ENDO 2023	23-06-21	CI
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-28	CI
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-28	CI
Crinetics Pharmaceuticals, Inc. Provides Update on Crn04777 Program	22-11-28	CI
Crinetics Pharmaceuticals Q3 Loss Widens	22-11-14	MT
Crinetics Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Crinetics Pharmaceuticals, Inc. Completes Enrollment in Phase 3 PATHFNDR-1 Study	22-10-13	CI
Crinetics Pharmaceuticals' CRN04777 Receives Innovation Passport in UK to Treat Congenital Hyperinsulinism	22-10-06	MT
Crinetics Pharmaceuticals, Inc Announces that Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism	22-10-06	CI
Crinetics Pharmaceutics, Inc. Enters into Lease Agreement with San Diego 1 Llc for Laboratory and Office Space Located At 6055 Lusk Blvd., San Diego, California	22-09-15	CI
Crinetics Pharmaceuticals Announces New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly	22-09-06	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Crinetics Pharmaceuticals, Inc.

Equities

CRNX

US22663K1079

Highlights

Filters